Feature | March 12, 2013

Mayo Study Questions if Imaging Agents Cause Acute Kidney Injury

Contrast Agents Mayo Clinic Clinical Study Kidney Injury

March 12, 2013 — Many physicians have long believed that the use of intravenous contrast agents for computed tomography (CT) scans can cause acute kidney injury. New Mayo Clinic research questions the strength of the causal link between the two. The findings from two tandem studies are published online in the journal Radiology.

The first study examined all previous research that compared patients who did or did not receive contrast agents, while the second paper represented a new retrospective study of over 100,000 CT scans performed at Mayo Clinic from 2000 to 2010, the largest published study to date examining the effect of contrast-enhanced imaging on renal function. In the retrospective study, researchers performed statistical analyses to study causality and mimic a randomized controlled trial to better match patients who received contrast agents to those patients who did not. These techniques had not been performed in any prior studies of renal function following contrast administration.

“These studies have significant clinical ramifications with regard to who is eligible to receive contrast media during CT exams,” says lead co-author Bob McDonald, M.D., Ph.D., a radiologist at Mayo Clinic. “Despite limited clinical evidence, contrast is commonly withheld during CT exams of individuals with even modest renal impairment due to concern for kidney injury, often at the expense of diagnostic accuracy of the exam. Our goal for these studies was to provide better evidence regarding the true incidence of renal injury following intravenous contrast administration and better define the ‘at-risk’ patient population.”

In both studies, Mayo Clinic researchers found that patients who received intravenous contrast agents and those who didn’t had a similar risk of developing acute kidney injury.

“Our findings suggest that, if contrast-induced nephropathy exists at all, it is likely rare and cannot be easily identified from unrelated causes of renal injury,” says lead co-author Jennifer McDonald, Ph.D., a radiology associate at Mayo Clinic. “Hopefully our findings can promote additional research to help redefine the safety window of contrast media and, in turn, improve patient care through more frequent use of appropriate clinical imaging.”

For more information: www.mayoclinic.org/about, www.mayoclinic.org/news

Related Content

Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Hitachi Supria True64 CT Receives FDA Clearance
Technology | Computed Tomography (CT) | September 15, 2017
September 15, 2017 — Hitachi Healthcare Americas Inc. announced it has attained U.S.
Matrix Analytics Beginning Validation of Deep Learning Lung CT Tools
News | Lung Cancer | September 13, 2017
Matrix Analytics announced it will clinically validate its LungDirect deep learning and predictive analytics tools for...
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
Orange County, Calif. Hospital Adopts Siemens Somatom Force CT for Cardiac Imaging
News | Computed Tomography (CT) | September 12, 2017
Hoag Memorial Hospital Presbyterian recently became the first hospital in Orange County, Calif., to install the Siemens...
Patient X-ray radiation exposure from medical imaging has been a hot topic in radiology and has prompted the implementation of radiation dose monitoring systems.
Feature | Radiation Dose Management | September 08, 2017 | By Dave Fornell
Patient X-ray radiation exposure from medical imaging has been a hot topic in radiology and has prompted the...
Technology | Radiation Dose Management | September 07, 2017
September 7, 2017 — Sapheneia and Scannerside received U.S.
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
September 6, 2017 — Guerbet LLC USA announced that the U.S.
Overlay Init